Venus Remedies rose 4.59% to Rs 276.85 at 14:17 IST on BSE on bargain hunting after the stock fell 14.24% in the preceding five trading sessions to Rs 264.70 on 25 September 2014, from a recent high of Rs 308.65 on 18 September 2014.
Meanwhile, the BSE Sensex was down 41.15 points, or 0.16%, to 26,427.21.
On BSE, so far 1.37 lakh shares were traded in the counter, compared with an average volume of 99,072 shares in the past one quarter.
The stock hit a high of Rs 290.70 and a low of Rs 261.50 so far during the day. The stock hit a 52-week high of Rs 381.75 on 15 September 2014. The stock hit a 52-week low of Rs 180 on 30 September 2013.
The stock had outperformed the market over the past one month till 25 September 2014, rising 1.83% compared with 0.12% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, rising 0.44% as against Sensex's 4.56% rise.
The small-cap company has an equity capital of Rs 11.44 crore. Face value per share is Rs 10.
Venus Remedies' net profit fell 33.1% to Rs 10.25 crore on 4.6% decline in net sales to Rs 120.81 crore in Q1 June 2014 over Q1 June 2013.
Venus Remedies is a fully integrated pharmaceutical company. It manufactures products in critical care segments such as anti cancer, anti infective, neurology, skin & wound care, and pain management.
Powered by Capital Market - Live News
